Published in J Natl Cancer Inst Monogr on January 01, 2006
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2014) 3.46
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48
Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. J Natl Cancer Inst (2015) 1.42
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst (2014) 1.04
Socioeconomic disparities in the decline in invasive breast cancer incidence. Breast Cancer Res Treat (2010) 0.96
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med (2016) 0.92
Modeling the impact of population screening on breast cancer mortality in the United States. Breast (2011) 0.87
Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention. Cancer (2013) 0.80
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. Pharmacoeconomics (2013) 0.76
Using Active Learning for Speeding up Calibration in Simulation Models. Med Decis Making (2015) 0.75
Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. Leuk Lymphoma (2015) 0.75
Tumour doubling times and the length bias in breast cancer screening programmes. Health Care Manag Sci (2011) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med (2005) 16.70
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (2011) 15.45
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst (2002) 6.87
Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol (2011) 5.46
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet (2003) 4.20
A model for a smallpox-vaccination policy. N Engl J Med (2002) 3.79
Estimating average annual per cent change in trend analysis. Stat Med (2009) 3.54
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25
Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst (2002) 3.04
Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev (2009) 3.04
Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology (2012) 2.98
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol (2009) 2.74
Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev (2011) 2.62
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst (2010) 2.59
Estimating average annual percent change for disease rates without assuming constant change. Biometrics (2006) 2.51
Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes Dev (2009) 2.46
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst (2008) 2.23
Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev (2007) 2.21
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Comparability of segmented line regression models. Biometrics (2004) 2.12
Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev (2011) 2.06
Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ (2012) 2.05
Age-conditional probabilities of developing cancer. Stat Med (2003) 2.03
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part I--All cancers among men. J Natl Cancer Inst (2002) 1.97
Individualizing colonoscopy screening by sex and race. Gastrointest Endosc (2009) 1.96
Boolean implication networks derived from large scale, whole genome microarray datasets. Genome Biol (2008) 1.91
At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer (2009) 1.88
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2011) 1.85
Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst (2008) 1.83
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst (2010) 1.83
National Polyp Study data: evidence for regression of adenomas. Int J Cancer (2004) 1.83
Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. BMJ (2009) 1.81
A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making (2011) 1.77
Bias associated with self-report of prior screening mammography. Cancer Epidemiol Biomarkers Prev (2009) 1.75
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population. Risk Anal (2012) 1.74
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
SELECTING THE NUMBER OF CHANGE-POINTS IN SEGMENTED LINE REGRESSION. Stat Sin (2009) 1.69
A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol (2012) 1.67
Extracting binary signals from microarray time-course data. Nucleic Acids Res (2007) 1.67
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev (2010) 1.66
Discovering biological progression underlying microarray samples. PLoS Comput Biol (2011) 1.65
Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control (2006) 1.64
Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr (2006) 1.61
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res (2008) 1.58
Modeling the dissemination of mammography in the United States. Cancer Causes Control (2005) 1.52
The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr (2006) 1.47
Next generation analytic tools for large scale genetic epidemiology studies of complex diseases. Genet Epidemiol (2011) 1.47
A new method of predicting US and state-level cancer mortality counts for the current calendar year. CA Cancer J Clin (2004) 1.42
Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer (2002) 1.41
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41
The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res (2004) 1.39
A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer (2009) 1.37
Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care (2008) 1.37
Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology (2014) 1.36
Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol (2012) 1.35
A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin (2007) 1.33
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal (2012) 1.31
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr (2006) 1.30
Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol (2013) 1.29
Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res (2012) 1.28
Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst (2002) 1.24
Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis. J Natl Cancer Inst Monogr (2006) 1.23
The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis. Cancer (2005) 1.22
Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. Am J Epidemiol (2012) 1.21
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood (2013) 1.20
Breast cancer survivors in the United States: geographic variability and time trends, 2005-2015. Cancer (2009) 1.19
Dynamic microsimulation models for health outcomes: a review. Med Decis Making (2010) 1.18
Developing and interpreting models to improve diagnostics in developing countries. Nature (2006) 1.18
Cure fraction estimation from the mixture cure models for grouped survival data. Stat Med (2004) 1.18
Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst (2013) 1.16
MiDReG: a method of mining developmentally regulated genes using Boolean implications. Proc Natl Acad Sci U S A (2010) 1.15